Catalyst Pharmaceuticals, Inc. (CPRX)Healthcare | Biotechnology | Coral Gables, United States | NasdaqCM
31.48 USD
+0.01
(0.032%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 31.49 +0.01 (0.032%) ⇧ (July 13, 2026, 7:34 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:10 a.m. EDT
Catalyst Pharmaceuticals presents a compelling case for long-term capital appreciation driven by exceptional fundamentals and a pristine multi-year price trajectory. The company boasts a fortress balance sheet with minimal debt, robust free cash flow, and a return on equity exceeding 24%, all while trading at a forward P/E of under 10x—a stark discount to its earnings power. The price history confirms this quality, showing a relentless nine-year upward trend with no recent years of decline, reflecting consistent market validation of its business model. While the stock is currently range-bound near its 52-week highs, the technical setup remains constructive, sitting above key moving averages. However, the absence of a dividend yield makes it unsuitable for income-focused portfolios. The options market is screaming bullishness, with heavy positioning in far-out calls that suggests traders are pricing in a significant catalyst or continued expansion beyond current analyst targets. This convergence of deep value, superior execution, and aggressive speculative interest creates a high-conviction setup for growth investors. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.060350 |
| AutoARIMA | 0.061267 |
| AutoTheta | 0.069200 |
| AutoETS | 0.071088 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 1.85 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 5.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.265 |
| Revenue per Share | 4.874 |
| Market Cap | 3,853,701,376 |
| Trailing P/E | 18.20 |
| Forward P/E | 9.90 |
| Beta | 0.74 |
| Profit Margins | 37.08% |
| Website | https://catalystpharma.com |
As of July 11, 2026, 3:10 a.m. EDT: Speculators are overwhelmingly bullish, evidenced by massive open interest in out-of-the-money calls (strikes $35 and beyond) compared to negligible put activity. The call chain shows significant volume at distant strikes, suggesting a bet on a substantial upside move, while the put side is virtually dormant except for a few deep out-of-the-money contracts, indicating a lack of fear regarding downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4555967 |
| Address1 | 355 Alhambra Circle |
| Address2 | Suite 801 |
| All Time High | 32.56 |
| All Time Low | 0.37 |
| Ask | 31.49 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Daily Volume10 Day | 2,178,720 |
| Average Daily Volume3 Month | 2,409,077 |
| Average Volume | 2,409,077 |
| Average Volume10Days | 2,178,720 |
| Beta | 0.742 |
| Bid | 27.06 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 8.288 |
| City | Coral Gables |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 31.48 |
| Current Ratio | 7.103 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 31.49 |
| Day Low | 31.47 |
| Debt To Equity | 0.265 |
| Display Name | Catalyst Pharmaceuticals |
| Earnings Call Timestamp End | 1,778,589,000 |
| Earnings Call Timestamp Start | 1,778,589,000 |
| Earnings Growth | 0.111 |
| Earnings Quarterly Growth | 0.123 |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,785,960,000 |
| Earnings Timestamp Start | 1,785,960,000 |
| Ebitda | 305,828,992 |
| Ebitda Margins | 0.51230997 |
| Enterprise To Ebitda | 10.134 |
| Enterprise To Revenue | 5.192 |
| Enterprise Value | 3,099,375,616 |
| Eps Current Year | 3.1741 |
| Eps Forward | 3.18107 |
| Eps Trailing Twelve Months | 1.73 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 31.0766 |
| Fifty Day Average Change | 0.40340042 |
| Fifty Day Average Change Percent | 0.012980842 |
| Fifty Two Week Change Percent | 45.55967 |
| Fifty Two Week High | 32.56 |
| Fifty Two Week High Change | -1.0800018 |
| Fifty Two Week High Change Percent | -0.033169586 |
| Fifty Two Week Low | 19.05 |
| Fifty Two Week Low Change | 12.43 |
| Fifty Two Week Low Change Percent | 0.6524935 |
| Fifty Two Week Range | 19.05 - 32.56 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,162,996,200,000 |
| Float Shares | 115,583,952 |
| Forward Eps | 3.18107 |
| Forward P E | 9.896041 |
| Free Cashflow | 171,809,872 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 182 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.84036005 |
| Gross Profits | 501,657,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05574 |
| Held Percent Institutions | 0.89574 |
| Implied Shares Outstanding | 122,417,458 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. |
| Long Name | Catalyst Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 3,853,701,376 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_5103575 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 221,323,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,852,477,403 |
| Number Of Analyst Opinions | 3 |
| Open | 31.48 |
| Operating Cashflow | 208,214,000 |
| Operating Margins | 0.49021 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 305 420 3200 |
| Post Market Change | 0.0102005005 |
| Post Market Change Percent | 0.032403115 |
| Post Market Price | 31.4902 |
| Post Market Time | 1,783,985,693 |
| Previous Close | 31.47 |
| Price Eps Current Year | 9.917772 |
| Price Hint | 2 |
| Price To Book | 3.7982624 |
| Price To Sales Trailing12 Months | 6.455565 |
| Profit Margins | 0.37075 |
| Quick Ratio | 6.701 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0100002 |
| Regular Market Change Percent | 0.031777 |
| Regular Market Day High | 31.49 |
| Regular Market Day Low | 31.47 |
| Regular Market Day Range | 31.47 - 31.49 |
| Regular Market Open | 31.48 |
| Regular Market Previous Close | 31.47 |
| Regular Market Price | 31.48 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 3,371,477 |
| Return On Assets | 0.16268 |
| Return On Equity | 0.24496001 |
| Revenue Growth | 0.056 |
| Revenue Per Share | 4.874 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 122,417,458 |
| Shares Percent Shares Out | 0.0641 |
| Shares Short | 7,845,889 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 8,189,325 |
| Short Name | Catalyst Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0678 |
| Short Ratio | 4.11 |
| Source Interval | 15 |
| State | FL |
| Symbol | CPRX |
| Target High Price | 32.0 |
| Target Low Price | 31.5 |
| Target Mean Price | 31.66667 |
| Target Median Price | 31.5 |
| Total Cash | 755,859,008 |
| Total Cash Per Share | 6.176 |
| Total Debt | 2,681,000 |
| Total Revenue | 596,958,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.73 |
| Trailing P E | 18.196531 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 25.23175 |
| Two Hundred Day Average Change | 6.248249 |
| Two Hundred Day Average Change Percent | 0.24763438 |
| Type Disp | Equity |
| Volume | 3,371,477 |
| Website | https://catalystpharma.com |
| Zip | 33,134 |